Skip to main content

Viral Hepatitis: Hepatitis B (& D)

  • Chapter
  • First Online:
  • 1577 Accesses

Abstract

The field of viral hepatitis including that of hepatitis B is rapidly evolving. There continues to be an explosion of new information not only on treatment options but also on management of those with acute and/or chronic hepatitis B. In light of this, the focus of this chapter is not on addressing information typically in textbooks of hepatology but rather on a framework of specific patient management questions which may be faced by the provider in the care of the patient affected by hepatitis B infection.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lada O, Benhamou Y, Poynard T, Thibault V. Coexistance of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of “a” determinant variants. J Virol. 2006;80(6):2968–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Galati G, Vincentis A, Vespasiani-Gentilucci U, Gallo P, Vincenti D, Solmone M, et al. Coexistance of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. BMC Gastroenterol. 2014;14(94):1–4.

    Google Scholar 

  3. Colson P, Borentain P, Motte A, Henry M, Moal V, Botta-Fridlund D, et al. Clinical and virological significance of the co-existance of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology. 2007;367:30–40.

    Article  CAS  PubMed  Google Scholar 

  4. Hoofnagle J, Doo E, Liang J, Fleischer R, Lok A. Management of hepatitis B; summary of clinical research workshop. Hepatology. 2007;45(4):1056–75.

    Article  CAS  PubMed  Google Scholar 

  5. Reddy K, Beavers K, Hammond S, Lim J, Falck-Ytter Y. American Gastroenterological Association Institute Guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppresive drug therapy. Gastroenterology. 2015;148(1):215–9.

    Article  CAS  PubMed  Google Scholar 

  6. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–30.

    Article  PubMed  Google Scholar 

  7. LeFevre M. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventative Services Task Force Recommendation Statement. Ann Intern Med. 2014;161(1):58–67.

    Article  PubMed  Google Scholar 

  8. Maruyama T, Schodel F, Iino S, Koike K, Yasuda K, Peterson D, et al. Distinguishing between acute and symptomatic chronic hepatitis B virus infection. Hepatology. 1988;8(4):766–70.

    Article  Google Scholar 

  9. Draelos M, Morgan T, Schifman R, Sampliner R. Significance of isolated antibody to hepatits B core antigen determined by immune response to hepatitis B vaccination. JAMA. 1987;258(9):1193–5.

    Article  CAS  PubMed  Google Scholar 

  10. Al-Mekhaizeem K, Miriello M, Sherker A. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. Can Med Assoc J. 2001;165(8):1063–4.

    CAS  Google Scholar 

  11. Lok A, McMahon J. AASLD practice guidelines: chronic hepatitis B. Hepatology. 2007;45(2):507–39.

    Article  CAS  PubMed  Google Scholar 

  12. Al-Mahtab M, Rahman S, Akbar S, Kamal M, Khan M. Clinical use of liver biopsy for the diagnosis and management of inactive and aymptomatic hepatitis B virus carriers in Bangladesh. J Med Virol. 2010;82:1350–4.

    Article  PubMed  Google Scholar 

  13. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.

    Article  PubMed  Google Scholar 

  14. Mast E, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR. 2006;54(RR16):1–23.

    Google Scholar 

  15. Sarkar M, Terrault N. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology. 2014;60(2):448–51.

    Article  PubMed  Google Scholar 

  16. Reddy K, Pavri T. Long-term safety of HBV therapies and when to stop therapy. Crit Issues HBV. 2014;1(1):17–9.

    Google Scholar 

  17. Sorrell M, Belongia E, Costa J, Gareen I, Grem J, Inadomi J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150(2):104–10.

    Article  PubMed  Google Scholar 

  18. Chu C, Liaw Y. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26(2):142–52.

    Article  CAS  PubMed  Google Scholar 

  19. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107.

    Article  CAS  PubMed  Google Scholar 

  20. Keefe E, Dieterich D, Han S, Jacobson I, Martin P, Schiff E, et al. A treatment algoright for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2(2):87–106.

    Article  Google Scholar 

  21. Wong R, Gish R. Implementing best practices when initiating hepatitis B virus therapy. Crit Issues HBV. 2014;1(1):5–10.

    Google Scholar 

  22. Lau D, Javaid A. Evaluating underlying causes of HBV treatment failure. Crit Issues HBV. 2014;1(1):13–5.

    Google Scholar 

  23. Lok A, McMajon B. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    Article  PubMed  Google Scholar 

  24. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53(3):449.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Venelin Kounev M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Taranukha, T., Kounev, V. (2017). Viral Hepatitis: Hepatitis B (& D). In: Saeian, K., Shaker, R. (eds) Liver Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-30103-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30103-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30101-3

  • Online ISBN: 978-3-319-30103-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics